Market revenue in 2022 | USD 6,306.0 million |
Market revenue in 2030 | USD 10,747.9 million |
Growth rate | 6.9% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.95% in 2022. Horizon Databook has segmented the Europe hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Market growth in Europe is likely to be driven by growing prevalence of target diseases, strong presence of global market players in the region, and increased awareness about novel therapeutic options such as hormone replacement therapy among individuals.
Government organizations, such as National Health Services (NHS) and National Organization for Rare Disorders (NORD), are raising awareness about growth disorders, including GHD, Turner syndrome, & Prader-Willi syndrome.
Moreover, in December 2021, EMA'S CHMP issued a positive opinion recommending somatrogon for marketing authorization in European countries. Such initiatives are expected to accelerate approval process of HGH therapies in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe hormone replacement therapy market , including forecasts for subscribers. This continent databook contains high-level insights into Europe hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account